The PD-1/PD-L1 axis in the pathogenesis of urothelial bladder cancer and evaluating its potential as a therapeutic target.

"...anti-PD-L1 is a highly promising therapy in urothelial bladder cancer. The wealth of upcoming clinical trials highlights the global scientific enthusiasm surrounding this therapeutic approach which may dramatically improve the lives of urothelial bladder cancer patients in the near future."

[1]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[2]  S. Abdulkadir,et al.  Emerging therapeutic targets in bladder cancer. , 2015, Cancer treatment reviews.

[3]  W. Liang,et al.  Prognostic Significance of Programmed Cell Death 1 (PD-1) or PD-1 Ligand 1 (PD-L1) Expression in Epithelial-Originated Cancer , 2015, Medicine.

[4]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[5]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[6]  L. Zitvogel,et al.  Targeting PD-1/PD-L1 interactions for cancer immunotherapy , 2012, Oncoimmunology.

[7]  J. Machiels,et al.  Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[9]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[10]  C. Pashos,et al.  The health economics of bladder cancer , 2012, PharmacoEconomics.

[11]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[12]  W. Shipley,et al.  Bladder cancer , 2009, The Lancet.

[13]  L. Kiemeney,et al.  The present and future burden of urinary bladder cancer in the world , 2009, World Journal of Urology.

[14]  Haiyang Xie,et al.  TLR4 Signaling Induces B7-H1 Expression Through MAPK Pathways in Bladder Cancer Cells , 2008, Cancer investigation.

[15]  B. Quesnel,et al.  Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. , 2007, Blood.

[16]  Haidong Dong,et al.  PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomata , 2007, Cancer.

[17]  P. Mischel,et al.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.

[18]  Koichiro Matsumoto,et al.  Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers , 2007, Cancer Immunology, Immunotherapy.

[19]  G. Collins.  The next generation. , 2006, Scientific American.

[20]  Yoshimasa Tanaka,et al.  Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Haidong Dong,et al.  Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.